Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.
Saved in:
| Title: | Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population. |
|---|---|
| Authors: | Waddell T; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Pillai M; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Armitage K; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Graham DM; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.; University of Manchester, Manchester, UK., Moran M; Pfizer GmbH, Linkstraße 10, Berlin, 10785, Germany., Dilleen M; Pfizer, Global Product Development, Sandwich, UK., Holmes S; Pfizer Oncology, Surrey, UK., Śleszyńska-Dopiera E; Quanticate, Warsaw, Poland., Hawkins R; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.; University of Manchester, Manchester, UK. |
| Source: | Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (33), pp. 2547-2558. Date of Electronic Publication: 2024 Oct 09. |
| Publication Type: | Clinical Trial; Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-8301 |
|---|---|
| DOI: | 10.1080/14796694.2024.2385882 |
